Congress Asset Management Co. Has $150.95 Million Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Congress Asset Management Co. lifted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 307,266 shares of the medical equipment provider’s stock after buying an additional 2,868 shares during the period. Intuitive Surgical comprises about 1.0% of Congress Asset Management Co.’s holdings, making the stock its 21st largest position. Congress Asset Management Co.’s holdings in Intuitive Surgical were worth $150,951,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Catalyst Financial Partners LLC boosted its stake in shares of Intuitive Surgical by 4.8% in the 3rd quarter. Catalyst Financial Partners LLC now owns 1,852 shares of the medical equipment provider’s stock worth $910,000 after buying an additional 85 shares during the last quarter. Goldstone Financial Group LLC purchased a new stake in shares of Intuitive Surgical during the 3rd quarter valued at $235,000. Oak Harvest Investment Services boosted its holdings in shares of Intuitive Surgical by 0.8% in the 3rd quarter. Oak Harvest Investment Services now owns 9,376 shares of the medical equipment provider’s stock worth $4,606,000 after buying an additional 77 shares during the last quarter. SteelPeak Wealth LLC raised its position in Intuitive Surgical by 262.3% in the third quarter. SteelPeak Wealth LLC now owns 27,570 shares of the medical equipment provider’s stock worth $13,544,000 after acquiring an additional 19,960 shares during the period. Finally, Diversify Wealth Management LLC raised its holdings in shares of Intuitive Surgical by 30.5% in the 3rd quarter. Diversify Wealth Management LLC now owns 3,997 shares of the medical equipment provider’s stock worth $2,049,000 after purchasing an additional 934 shares during the period. 83.64% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 188 shares of the firm’s stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $506.52, for a total transaction of $95,225.76. Following the completion of the sale, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,788,899.12. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Robert Desantis sold 188 shares of Intuitive Surgical stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $506.52, for a total value of $95,225.76. Following the completion of the sale, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,788,899.12. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Amy L. Ladd sold 450 shares of the firm’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $490.28, for a total value of $220,626.00. Following the completion of the transaction, the director now owns 821 shares in the company, valued at approximately $402,519.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,095 shares of company stock valued at $24,552,712 in the last quarter. 0.80% of the stock is owned by insiders.

Intuitive Surgical Stock Performance

Shares of ISRG traded down $4.19 during mid-day trading on Thursday, reaching $509.58. The company had a trading volume of 99,775 shares, compared to its average volume of 1,456,410. The firm has a 50-day moving average price of $489.74 and a 200 day moving average price of $445.30. The company has a market capitalization of $181.50 billion, a price-to-earnings ratio of 82.60, a price-to-earnings-growth ratio of 5.11 and a beta of 1.39. Intuitive Surgical, Inc. has a 52 week low of $260.17 and a 52 week high of $523.34.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Evercore ISI reaffirmed a “cautious” rating on shares of Intuitive Surgical in a research report on Friday, October 18th. Citigroup increased their target price on shares of Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Wells Fargo & Company increased their target price on Intuitive Surgical from $466.00 to $549.00 and gave the company an “overweight” rating in a research note on Friday, October 18th. Royal Bank of Canada lifted their price target on Intuitive Surgical from $525.00 to $555.00 and gave the stock an “outperform” rating in a research note on Friday, October 18th. Finally, Stifel Nicolaus increased their price objective on Intuitive Surgical from $475.00 to $525.00 and gave the company a “buy” rating in a research report on Friday, October 18th. One analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $513.74.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.